Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.31
FLDM's Cash to Debt is ranked lower than
82% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.24 vs. FLDM: 0.31 )
Ranked among companies with meaningful Cash to Debt only.
FLDM' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 1.01 Max: No Debt
Current: 0.31
Equity to Asset 0.17
FLDM's Equity to Asset is ranked lower than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. FLDM: 0.17 )
Ranked among companies with meaningful Equity to Asset only.
FLDM' s Equity to Asset Range Over the Past 10 Years
Min: -7.63  Med: 0.17 Max: 0.89
Current: 0.17
-7.63
0.89
F-Score: 2
Z-Score: 0.26
M-Score: -3.48
WACC vs ROIC
17.90%
-35.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -70.08
FLDM's Operating margin (%) is ranked lower than
71% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. FLDM: -70.08 )
Ranked among companies with meaningful Operating margin (%) only.
FLDM' s Operating margin (%) Range Over the Past 10 Years
Min: -323.38  Med: -44.12 Max: -26.2
Current: -70.08
-323.38
-26.2
Net-margin (%) -72.75
FLDM's Net-margin (%) is ranked lower than
70% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. FLDM: -72.75 )
Ranked among companies with meaningful Net-margin (%) only.
FLDM' s Net-margin (%) Range Over the Past 10 Years
Min: -349.84  Med: -51.39 Max: -23.22
Current: -72.75
-349.84
-23.22
ROE (%) -90.60
FLDM's ROE (%) is ranked lower than
82% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.29 vs. FLDM: -90.60 )
Ranked among companies with meaningful ROE (%) only.
FLDM' s ROE (%) Range Over the Past 10 Years
Min: -90.39  Med: -40.19 Max: -16.77
Current: -90.6
-90.39
-16.77
ROA (%) -22.42
FLDM's ROA (%) is ranked lower than
62% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. FLDM: -22.42 )
Ranked among companies with meaningful ROA (%) only.
FLDM' s ROA (%) Range Over the Past 10 Years
Min: -67.71  Med: -32.8 Max: -13.69
Current: -22.42
-67.71
-13.69
ROC (Joel Greenblatt) (%) -270.66
FLDM's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.97 vs. FLDM: -270.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLDM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -448.22  Med: -231.92 Max: -138.28
Current: -270.66
-448.22
-138.28
Revenue Growth (3Y)(%) 8.80
FLDM's Revenue Growth (3Y)(%) is ranked higher than
69% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.70 vs. FLDM: 8.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLDM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -40.9 Max: 20.4
Current: 8.8
0
20.4
EBITDA Growth (3Y)(%) 53.00
FLDM's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. FLDM: 53.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FLDM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -56.65 Max: 53
Current: 53
0
53
EPS Growth (3Y)(%) 59.10
FLDM's EPS Growth (3Y)(%) is ranked higher than
95% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. FLDM: 59.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FLDM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -55.3 Max: 59.1
Current: 59.1
0
59.1
GuruFocus has detected 5 Warning Signs with Fluidigm Corp $FLDM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FLDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FLDM Guru Trades in Q1 2016

Columbia Wanger 2,056,004 sh (+14.94%)
PRIMECAP Management 4,266,432 sh (unchged)
Jim Simons 108,000 sh (-47.32%)
Eaton Vance Worldwide Health Sciences Fund 527,700 sh (-19.19%)
» More
Q2 2016

FLDM Guru Trades in Q2 2016

Jim Simons 260,100 sh (+140.83%)
Eaton Vance Worldwide Health Sciences Fund Sold Out
PRIMECAP Management 4,250,732 sh (-0.37%)
Columbia Wanger 1,777,282 sh (-13.56%)
» More
Q3 2016

FLDM Guru Trades in Q3 2016

Jim Simons 370,300 sh (+42.37%)
PRIMECAP Management 4,265,332 sh (+0.34%)
Columbia Wanger Sold Out
» More
Q4 2016

FLDM Guru Trades in Q4 2016

Jim Simons 451,300 sh (+21.87%)
PRIMECAP Management 4,295,532 sh (+0.71%)
» More
» Details

Insider Trades

Latest Guru Trades with FLDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:QTNT, NAS:TTOO, NAS:FLGT, OTCPK:CLIFF, NAS:TRIB, AMEX:SENS, NAS:CTSO, OTCPK:CBIS, AMEX:VNRX, NAS:AIQ, NAS:PMD, OTCPK:EPGNF, NAS:RDNT, NAS:VRML, NAS:OXFD, NAS:ONVO, NAS:CEMI, NYSE:ENZ, NAS:TROV, AMEX:PTN » details
Traded in other countries:FLB.Germany,
Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies.

Fluidigm Corp is a Delaware Corporation formed in May, 1999. The Company develops, manufacture, and market microfluidic systems to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. These systems are designed to simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. The current markets for its products include life science research, clinical research, and Ag-Bio. The proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. The Company's primary area of development within life science research is genetic analysis, the study of genes and their functions. Genetic analysis techniques, such as SNP genotyping, genotyping by sequencing, and genotyping by real-time PCR analysis, have become increasingly useful in Ag-Bio applications, including wildlife population studies, agricultural quality control, and commercial genetic engineering and identification. It actively market four microfluidic systems, including 18 different commercial IFCs for nucleic acid analysis, as well as three families of assay chemistries. Its systems are based on one or more IFCs designed for particular applications and include specialized reagents, instrumentation, and software. The Company distributes its microfluidic systems through its direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. It has sold its C1 Single-Cell Auto Prep, BioMark, BioMark HD, EP1, and Access Array systems to the academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. The Company has sold approximately 920 systems to customers in over 35 countries. Its microfluidic systems and instrumentation for commercial sale, as well as for internal research and development purposes, are manufactured at its facilities in Singapore. The Company also manufactures IFCs for research and development and its assay chemistries at its headquarters in South San Francisco, California. It competes with companies such as Affymetrix, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Life Technologies Corporation (now part of Thermo Fisher Scientific), LGC Limited, Luminex Corporation, NanoString Technologies, Inc., PerkinElmer, Inc. (through its acquisition of Caliper Life Sciences, Inc.), RainDance Technologies, Inc., Roche Applied Science (a division of Roche Diagnostics Corporation), Sequenom, Inc., Thermo Fisher Scientific Inc., and WaferGen Bio-Systems, Inc.

Ratios

vs
industry
vs
history
P/B 3.61
FLDM's P/B is ranked higher than
59% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. FLDM: 3.61 )
Ranked among companies with meaningful P/B only.
FLDM' s P/B Range Over the Past 10 Years
Min: 1.46  Med: 4.68 Max: 12.54
Current: 3.61
1.46
12.54
P/S 1.83
FLDM's P/S is ranked higher than
77% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. FLDM: 1.83 )
Ranked among companies with meaningful P/S only.
FLDM' s P/S Range Over the Past 10 Years
Min: 0.93  Med: 5.9 Max: 16.74
Current: 1.83
0.93
16.74
Current Ratio 3.28
FLDM's Current Ratio is ranked higher than
60% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. FLDM: 3.28 )
Ranked among companies with meaningful Current Ratio only.
FLDM' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 4.35 Max: 8.73
Current: 3.28
1.13
8.73
Quick Ratio 2.60
FLDM's Quick Ratio is ranked higher than
59% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.26 vs. FLDM: 2.60 )
Ranked among companies with meaningful Quick Ratio only.
FLDM' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 3.87 Max: 8.11
Current: 2.6
0.86
8.11
Days Inventory 153.31
FLDM's Days Inventory is ranked lower than
75% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.91 vs. FLDM: 153.31 )
Ranked among companies with meaningful Days Inventory only.
FLDM' s Days Inventory Range Over the Past 10 Years
Min: 102.81  Med: 149.83 Max: 443.32
Current: 153.31
102.81
443.32
Days Sales Outstanding 51.06
FLDM's Days Sales Outstanding is ranked higher than
66% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. FLDM: 51.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.06  Med: 84.55 Max: 124.82
Current: 51.06
51.06
124.82
Days Payable 31.47
FLDM's Days Payable is ranked lower than
74% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.33 vs. FLDM: 31.47 )
Ranked among companies with meaningful Days Payable only.
FLDM' s Days Payable Range Over the Past 10 Years
Min: 31.47  Med: 74.66 Max: 283.05
Current: 31.47
31.47
283.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
FLDM's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. FLDM: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FLDM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.7  Med: -8.2 Max: 0
Current: -4.1
-143.7
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.31
FLDM's Price/Median PS Value is ranked higher than
94% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. FLDM: 0.31 )
Ranked among companies with meaningful Price/Median PS Value only.
FLDM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 0.93 Max: 2.32
Current: 0.31
0.34
2.32
Earnings Yield (Greenblatt) (%) -22.70
FLDM's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. FLDM: -22.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLDM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -25.92  Med: 0 Max: 0
Current: -22.7
-25.92
0

More Statistics

Revenue (TTM) (Mil) $104.4
EPS (TTM) $ -2.62
Beta4.10
Short Percentage of Float6.81%
52-Week Range $4.31 - 11.05
Shares Outstanding (Mil)29.12

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -2.10
EPS w/o NRI ($) -2.10
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for FLDM

Headlines

Articles On GuruFocus.com
Columbia Wanger Sold 2 Stakes in September Oct 07 2016 

More From Other Websites
DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues Feb 17 2017
DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4 Feb 17 2017
CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4 Feb 16 2017
Fluidigm Corp. :FLDM-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017 Feb 14 2017
Varian (VAR) Eclipse Software Named Category Leader by KLAS Feb 14 2017
FLUIDIGM CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Feb 10 2017
Edited Transcript of FLDM earnings conference call or presentation 8-Feb-17 10:00pm GMT Feb 08 2017
Fluidigm reports 4Q loss Feb 08 2017
Fluidigm reports 4Q loss Feb 08 2017
FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 08 2017
Fluidigm Announces Q4 and Full Year 2016 Financial Results Feb 08 2017
Q4 2016 Fluidigm Corp Earnings Release - After Market Close Feb 08 2017
Fluidigm to Report Q4 and Full Year 2016 Financial Results and Host Conference Call Jan 25 2017
Fluidigm: Q4 Preliminary Results Fail to Cheer Investors Jan 12 2017
FLUIDIGM CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jan 11 2017
FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017
Fluidigm Announces Preliminary Revenue for the Fourth Quarter and Full Year Ended December 31, 2016 Jan 09 2017
Fluidigm Unveils High-Throughput Integrated Fluidic Circuit Dec 22 2016
FLUIDIGM INTRODUCES A NEW MEDIUM-CELL HIGH-THROUGHPUT INTEGRATED FLUIDIC CIRCUIT Dec 21 2016
Fluidigm Introduces a New Medium-Cell High-Throughput Integrated Fluidic Circuit With Higher... Dec 21 2016
ETFs with exposure to Fluidigm Corp. : December 16, 2016 Dec 16 2016
Is Fluidigm Corporation (FLDM) A Good Stock To Buy? Dec 15 2016
5 Stocks Under $10 Poised for Big Breakouts Dec 01 2016
Fluidigm to Present at Piper Jaffray 28th Annual Healthcare Conference Nov 29 2016
FLUIDIGM CORPORATION ADOPTS TAX BENEFIT PRESERVATION PLAN Nov 22 2016
FLUIDIGM INTRODUCES HIGH-PARAMETER MAXPAR MASS CYTOMETRY Nov 10 2016
FLUIDIGM ANNOUNCES THIRD QUARTER FINANCIAL RESULTS Nov 03 2016
FLUIDIGM TO REPORT Q3 2016 FINANCIAL RESULTS Oct 24 2016
FLUIDIGM NAMES S. CHRISTOPHER LINTHWAITE AS NEW CEO Oct 19 2016
FLUIDIGM ANNOUNCES PRELIMINARY THIRD QUARTER 2016 REVENUE Oct 12 2016
NEW HIGH-THROUGHPUT TARGETED NGS LIBRARY PREPARATION SYSTEM Aug 04 2016
FLUIDIGM RECIEVES ISO 13485 AND ISO 9001 CERTIFICATION Aug 04 2016
FLUIDIGM APPOINTS NEW PRESIDENT AND CHIEF OPERATING OFFICER Aug 04 2016
FLUIDIGM ANNOUNCES Q2 2016 FINANCIAL RESULTS Aug 04 2016
FLUIDIGM TO ANNOUNCE Q2 2016 FINANCIAL RESULTS Jul 28 2016
FLUIDIGM INTRODUCES SINGLE-CELL TCR SEQUENCING Jun 13 2016
FLUIDIGM ANNOUNCES NEW CUSTOMER INSPIRATION CENTER Jun 13 2016
FLUIDIGM ANNOUNCES NEW CUSTOMER INSPIRATION CENTER Jun 09 2016
FLUIDIGM INTRODUCES SINGLE-CELL TCR SEQUENCING May 16 2016
FLUIDIGM ANNOUNCES FIRST QUARTER FINANCIAL RESULTS May 05 2016
FLUIDIGM TO ANNOUNCE Q1 2016 FINANCIAL RESULTS Apr 22 2016
FLUIDIGM ANNOUNCES NEW INTEGRATED FLUIDIC CIRCUITS Apr 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)